Patents by Inventor Peng Cho Tang

Peng Cho Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9566277
    Abstract: A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof are described.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: February 14, 2017
    Assignee: Jiangsu Hansoh Pharmaceutical Co., Ltd.
    Inventors: Peng Cho Tang, Xin Li, Xiangqin Li, Yang Chen, Bin Wang, Zhe Zhu
  • Patent number: 9517988
    Abstract: The present invention relates to a phenol derivative and the preparation method and use in medicine thereof, and particular to a phenol derivative represented by general formula (A) or a stereoisomer, a solvate, a metabolite, a prodrug, a pharmaceutically acceptable salt or a cocrystal thereof, a preparation method thereof, a pharmaceutical composition comprising the same, and use of the compound or composition of the present invention in the field of the central nervous system; wherein the definitions of substituents in general formula (A) are the same as those in the Description.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: December 13, 2016
    Assignee: Sichuan Haisco Pharmaceutical Co., Ltd.
    Inventors: Linlin Qin, Fangqiong Li, Shixu Yi, Huadong Luo, Xinfeng Luo, Songlin Wan, Lei Ren, Guoliang Liu, Yonggang Wei, Jianyu Liu, Peng Cho Tang
  • Publication number: 20160151367
    Abstract: A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof are described.
    Type: Application
    Filed: February 5, 2016
    Publication date: June 2, 2016
    Inventors: Peng Cho TANG, Xin LI, Xiangqin LI, Yang CHEN, Bin WANG, Zhe ZHU
  • Publication number: 20160060197
    Abstract: The present invention relates to a phenol derivative and the preparation method and use in medicine thereof, and particular to a phenol derivative represented by general formula (A) or a stereoisomer, a solvate, a metabolite, a prodrug, a pharmaceutically acceptable salt or a cocrystal thereof, a preparation method thereof, a pharmaceutical composition comprising the same, and use of the compound or composition of the present invention in the field of the central nervous system; wherein the definitions of substituents in general formula (A) are the same as those in the Description.
    Type: Application
    Filed: November 9, 2015
    Publication date: March 3, 2016
    Applicant: Sichuan Haisco Pharmaceutical Co., Ltd.
    Inventors: Linlin QIN, Fangqiong LI, Shixu YI, Huadong LUO, Xinfeng LUO, Songlin WAN, Lei REN, Guoliang LIU, Yonggang WEI, Jianyu LIU, Peng Cho TANG
  • Patent number: 9273052
    Abstract: A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof are described.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: March 1, 2016
    Assignee: Jiangsu Hansoh Pharmaceutical Co., Ltd.
    Inventors: Peng Cho Tang, Xin Li, Xiangqin Li, Yang Chen, Bin Wang, Zhe Zhu
  • Patent number: 9120762
    Abstract: The pharmaceutically acceptable salts of bicycle-substituted pyrazolon azo derivatives represented by the general formula (I), their preparation methods, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics and their use as agonists of thrombopoietin receptor. The definitions of substituents in the general formula (I) are the same as the description.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: September 1, 2015
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Peng Cho Tang, Hejun Lü, Hongbo Fei, Yiqian Chen
  • Patent number: 8901140
    Abstract: 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof are disclosed. Specifically, the present disclosure discloses novel 6-amino quinazoline or 3-cyano quinoline derivatives presented by general formula (I), or tautomers, enantiomers, diastereomers, racemates or pharmaceutically acceptable salts thereof, or metabolites, metabolic precursors or prodrugs thereof, and their uses as treatment agents especially as protein kinase inhibitors, in which each substitutent group of general formula (I) is as defined in the specification.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: December 2, 2014
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Peng Cho Tang, Xin Li, Bin Wang, Jun Wang, Lijun Chen
  • Publication number: 20140140953
    Abstract: The pharmaceutically acceptable salts of bicycle-substituted pyrazolon azo derivatives represented by the general formula (I), their preparation methods, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics and their use as agonists of thrombopoietin receptor. The definitions of substituents in the general formula (I) are the same as the description.
    Type: Application
    Filed: January 27, 2014
    Publication date: May 22, 2014
    Applicants: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Peng Cho Tang, Hejun Lü, Hongbo Fei, Yiqian Chen
  • Patent number: 8697692
    Abstract: The present invention relates to pyrrolo[3,2-c]pyridine-4-one 2-indolinone compounds of Formula (I) and their pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8 X, Y and have the meaning cited in the specification. Also disclosed are the pharmaceutical compositions containing the foregoing compounds, methods for the preparation and pharmaceutical use thereof, particularly as protein kinase inhibitors. Formula (I).
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: April 15, 2014
    Assignee: Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Peng Cho Tang, Yidong Su, Lei Zhang, Lu Xiao
  • Patent number: 8691822
    Abstract: Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: April 8, 2014
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Peng Cho Tang, Nong Zhang, Baolei Zhang, Weimin Wang, Hao Zheng, Lin Wu
  • Patent number: 8642637
    Abstract: The pharmaceutically acceptable salts of bicyclo-substituted pyrazolon azo derivatives represented by the general formula (I), their preparation methods, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics and their use as agonists of thrombopoietin receptor. The definitions of substituents in the general formula (I) are the same as the description.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: February 4, 2014
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Peng Cho Tang, Hejun Lü, Hongbo Fei, Yiqian Chen
  • Patent number: 8609622
    Abstract: C-aryl glucoside derivatives, preparation processes and pharmaceutical uses thereof are disclosed. In particular, C-aryl glucoside derivatives represented by formula (I), with each substituent defined in the application, pharmaceutically acceptable salts or stereoisomers thereof, their preparation methods, and pharmaceutical compositions containing the derivatives as well as their uses as therapeutic agents, particularly as sodium-dependent glucose cotransporter (SGLT)-1 inhibitors, are disclosed.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: December 17, 2013
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Fanglong Yang, Peng Cho Tang, Qing Dong, Wangyang Tu, Jiang Fan, Dongliang Guan, Guangyuan Shen, Yang Wang, Jijun Yuan, Limin Zhang
  • Publication number: 20130303518
    Abstract: The invention provides a method of inhibiting the catalytic activity of a protein kinase comprising contacting said protein kinase with a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, and also provides a method of treating a protein kinase related disorder comprising a step of administering to a patient in need thereof a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, wherein each substituent in formula (I) is same as defined in the description.
    Type: Application
    Filed: September 27, 2012
    Publication date: November 14, 2013
    Applicants: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd.
    Inventors: Peng Cho Tang, Yidong Su, Yali Li, Lei Zhang, Fuqiang Zhao, Jialiang Yang, Ying Zhou, Pingyan Bie, Guangtao Qian, Minggang Ju
  • Patent number: 8518946
    Abstract: Pharmaceutically acceptable salts of (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-formic acid, their preparation methods, compositions containing the said pharmaceutical salts and their use as medicaments, especially as dipeptidyl peptidase IV (DPP-IV) inhibitors are disclosed. Of the many acceptable salts, one example is the following.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: August 27, 2013
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Peng Cho Tang, Piaoyang Sun, Fanglong Yang, Jindong Liang, Guangyuan Shen, Yang Wang, Jiang Fan
  • Patent number: 8513411
    Abstract: Tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I), their preparation methods, pharmaceutical compositions containing the derivatives and uses thereof as medicaments, especially as dipeptidyl peptidase IV inhibitors, wherein the substituents of formula (I) are defined as same as the description.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: August 20, 2013
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Peng Cho Tang, Fanglong Yang, Jiang Fan, Hu Feng, Yang Wang, Tao Yang
  • Publication number: 20130130997
    Abstract: C-aryl glucoside derivatives, preparation processes and pharmaceutical uses thereof are disclosed. In particular, C-aryl glucoside derivatives represented by formula (I), with each substituent defined in the application, pharmaceutically acceptable salts or stereoisomers thereof, their preparation methods, and pharmaceutical compositions containing the derivatives as well as their uses as therapeutic agents, particularly as sodium-dependent glucose cotransporter (SGLT)-1 inhibitors, are disclosed.
    Type: Application
    Filed: June 30, 2011
    Publication date: May 23, 2013
    Applicants: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Fanglong Yang, Peng Cho Tang, Qing Dong, Wangyang Tu, Jiang Fan, Dongliang Guan, Guangyuan Shen, Yang Wang, Jijun Yuan, Limin Zhang
  • Publication number: 20130131068
    Abstract: A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof are described.
    Type: Application
    Filed: July 26, 2011
    Publication date: May 23, 2013
    Applicant: JIANGSU HANSOH PHARMACEUTICAL CO., LTD.
    Inventors: Peng Cho Tang, Xin Li, Xiangqin Li, Yang Chen, Bin Wang, Zhe Zhu
  • Patent number: 8415349
    Abstract: The invention provides derivatives of azabicyclo alkane having formula (ID), and the method for making them, wherein each substitute in formula (ID) is same as defined in the description.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 9, 2013
    Assignee: Jiangsu Hansoh Pharmaceuticals Co., Ltd.
    Inventors: Peng Cho Tang, Zhigang Lin, Hejun Lü, Fuqiang Zhao, Li Li, Fanglong Yang, Jianghong Fu, Lin Wang, Guangyuan Shen, Dongliang Guan
  • Patent number: 8367710
    Abstract: The bicyclo-substituted pyrazolon-azo derivatives of formula (I) or pharmaceutical acceptable salts, hydrates or solvates thereof, methods for their preparation, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics and their use as agonists of thrombopoietin receptor are disclosed. The definition of substituents in formula (I) are the same as defined in the description.
    Type: Grant
    Filed: January 4, 2009
    Date of Patent: February 5, 2013
    Assignees: Jiangsu Hengrui Medicine Co. Ltd., Shanghai Hengrui Pharmaceutical Co. Ltd.
    Inventors: Peng Cho Tang, Hejun Lü, Hao Zheng, Yiqian Chen, Hongbo Fei, Shenglan Wang, Li Wang
  • Patent number: 8362251
    Abstract: The present invention relates to pyrrolo[3,2-c]pyridine-4-one 2-indolinone compounds of Formula (I) and their pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8 X, Y and have the meaning cited in the specification. Also disclosed are the pharmaceutical compositions containing the foregoing compounds, methods for the preparation and pharmaceutical use thereof, particularly as protein kinase inhibitors. Formula (I).
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: January 29, 2013
    Assignee: Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Peng Cho Tang, Yidong Su, Lei Zhang, Lu Xiao